LONDON--(Marketwire -03/20/12)- Lightlake Therapeutics Inc. (OTC.BB: LLTP.OB - News) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that the last patient involved in the Phase II Trial of the Company's proprietary treatment for Binge Eating Disorder is scheduled to be seen on March 27th, with the statistical analysis of the results of the Trial taking place thereafter.
"Completing this Phase II Trial will mark a major milestone for us," said Dr. Roger Crystal, Chief Executive Officer of Lightlake. "Our innovative nasal spray treatment has the potential to considerably improve the quality of life of those patients suffering from Binge Eating Disorder, which is the most common eating disorder in the U.S., affecting more than eight million people and accounting for three times the number of those diagnosed with anorexia and bulimia together."
Lightlake randomly selected 138 patients whom met the criteria for Binge Eating Disorder from over 900 applicants wanting to participate in the Phase II Trial, which is being held in Helsinki, Finland. Crown CRO, a Finnish Contract Research Organization involved in approximately 300 clinical studies over the years in addition to 90 clinical trials currently in progress, is providing the external validation for the Trial and Hannu Alho, professor of addiction medicine at the University of Helsinki, is serving as the lead investigator.
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.